Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Thrombosis caused by active rapamycin stents].

R Aoudia-Mentfakh1, F Raoux, J P Collet

  • 1Département de cardiologie médicale, institut de cardiologie, Paris.

Archives Des Maladies Du Coeur Et Des Vaisseaux
|March 23, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is the duration of dual antiplatelet therapy (DAPT) excessive in post-angioplasty in chronic coronary syndrome? Data from the France-PCI registry (2014-2019).

Frontiers in cardiovascular medicine·2023
Same author

Universal screening of newborns for biliary atresia: Cost-effectiveness of alternative strategies.

Journal of medical screening·2019
Same author

Management of antiplatelet therapy for non elective invasive procedures of bleeding complications: proposals from the French working group on perioperative haemostasis (GIHP), in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR).

Anaesthesia, critical care & pain medicine·2018
Same author

Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: "OLTAT registry".

International journal of cardiology·2018
Same author

Home-based screening for biliary atresia using infant stool colour cards: a large-scale prospective cohort study and cost-effectiveness analysis.

Journal of medical screening·2014
Same author

Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.

European heart journal·2013

Patients stopping anti-platelet therapy after rapamycin stent placement risk stent thrombosis. Continued dual anti-platelet therapy for 9 months and delaying surgery for 6 months post-stenting are recommended.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Vascular Medicine

Background:

  • Drug-eluting stents (DES), particularly those with rapamycin coatings, are widely used to prevent restenosis after percutaneous coronary intervention (PCI).
  • Anti-platelet therapy is crucial for stent patency, but its interruption, especially before major surgery, poses a significant risk.
  • Patient management involves balancing the benefits of revascularization with the risks of stent thrombosis and surgical complications.

Observation:

  • A 68-year-old patient experienced recurrent anterior myocardial infarction with cardiogenic shock due to rapamycin stent thrombosis 77 days post-angioplasty.
  • Stent thrombosis was precipitated by the cessation of dual anti-platelet therapy due to planned cancer recurrence surgery.
  • The patient had a history of diabetes mellitus, a known risk factor for cardiovascular events.

Related Experiment Videos

Findings:

  • Discontinuation of anti-platelet therapy, even with active stents, significantly increases the risk of stent thrombosis.
  • The optimal duration of dual anti-platelet therapy after rapamycin stent implantation appears to be at least 9 months.
  • A minimum waiting period of 6 months is advised between rapamycin stent revascularization and non-cardiac surgery.

Implications:

  • Continuation of dual anti-platelet therapy for at least 9 months is recommended following rapamycin stent implantation, irrespective of stent type.
  • Elective non-cardiac surgery should be postponed for at least 6 months after rapamycin stent procedures.
  • In cases where non-cardiac surgery is planned around the time of angioplasty, the use of active stents should be carefully reconsidered, potentially favoring bare-metal stents.